Mydecine reports that it's Phase IIa clinical trial is underway at three sites. Net loss for the year of CAD$26.9 million. Current cash ~CAD$30 million.
Psychedelics
The NEXT Psychedelic Stock To Uplist On The NASDAQ?
MindMed Inc has become the first psychedelics company to successfully uplist to the NASDAQ. Who will be the second...???
Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC
Numinus reports its Q2 2021 results. Cash balance of CAD$28.5 million. Net loss of CAD$4.2 million.
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth
MINDCURE updates investors on key elements of its business model, including its iSTRYM digital therapeutics platform and its emerging TBI research.
Small Pharma Completes Reverse Take-Over Transaction
UK-based Small Pharma Inc prepares to go public on the TSXV via RTO, having raised CAD$58 million for its qualifying transaction
Wesana Health and Debut Announce Receipt of Conditional Approval for CSE Listing
Wesana Health obtains conditional approval from the CSE to commence trading, via RTO with Debut Diamonds (CSE:DDI).
COMPASS Pathways launches proposed public offering
Compass Pathways plans to issue 4,000,000 new shares via prospectus, with an option to sell an additional 600,000 shares.
Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1
Psyched Wellness continues pre-clinical work on its AME-1 extract.
Second-Chance Buying Opportunity With Psychedelic Stock Warrants
In 2020, investors were able to reap spectacular returns from psychedelic stock warrants. With a new rally starting in the sector, a there is a NEW opportunity in these warrants.
Red Light Holland and Halo Collective Create Red Light Oregon, Inc. - Forwarding Intentions to Enter Oregon Medicinal Psychedelic Market
Red Light Holland seeks to enter the (legal) medicinal psilocybin market in Oregon.
MindMed Begins Trading on Nasdaq
MindMed Inc commences trading on the NASDAQ exchange under the symbol "MNMD".
Optimi Health Finalizes Planned Build-Out of Mushroom Production and Research Facility
Optimi Health gets closer to completion of its 20,000 sq. ft. production and research facility in British Columbia.
Drug Reform: Record (91%) American Support For Legalizing Medicinal Cannabis
U.S. support for legalizing cannabis for medicinal use has hit a new record-high: 91%. Strong bipartisan support. Next: psychedelic drugs.
Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab
Numinus' Phase I clinical trial will evaluate safety/tolerance properties of its Psilocybe mushroom product.
Jews, Christians, and Muslims Are Reclaiming Ancient Psychedelic Practices, And That Could Help With Legalization
A psychedelic trip can be among the most sacred experiences of a person’s life.